



# Non Clear Cell Clinical Trials in Canada

Daniel Heng MD MPH FRCPC MSC

Clinical Professor, University of Calgary

Medical Director, Clinical Research Unit, TBCC



UNIVERSITY OF  
CALGARY

Clear Cell

Non Clear Cell

Clear Cell

Non  
Clear  
Cell

# PAPMET

- First line metastatic papillary mRCC
- Type I and Type II
- Sunitinib
- Cabozantinib
- Crizotinib
- Savolitinib

Non Clear Cell

# PAPMET


- First line metastatic papillary mRCC
- Type I and Type II
- Sunitinib
- Cabozantinib
- ~~Crizotinib~~
- ~~Savolitinib~~

Non Clear Cell

# Recruitment

Total Trial CTN-wide 120/148

Canadian contribution so far 18 patients



|   |                      |      |   |
|---|----------------------|------|---|
| 1 | Bjarnason, Georg A.  | CAMN | 4 |
| 2 | Wood, Lori           | CABN | 2 |
| 2 | Winqvist, Eric W.    | CANL | 2 |
| 2 | Heng, Daniel         | CATC | 2 |
| 3 | Macfarlane, Robyn J. | CABN | 1 |
| 3 | Blais, Normand       | CAHN | 1 |
| 3 | Reaume, M. Neil      | CAKO | 1 |
| 3 | Kapoor, Anil         | CALJ | 1 |
| 3 | Ernst, Donald Scott  | CANL | 1 |
| 3 | Fernandes, Ricardo   | CANL | 1 |
| 3 | Potvin, Kylea R.     | CANL | 1 |
| 3 | Basappa, Naveen S.   | CATW | 1 |

# Other trials in non clear cell RCC

- Single agent pembrolizumab in non clear cell
  - Completed accrual
- SAVOIR
  - Savolitinib vs Sunitinib in papillary
  - Closed
- MSKCC: Phase II Nivo + cabozantinib in non clear cell
- Atez+Bev in non clear cell (UCSD)
- ANZUP: Nivo then Ipi Nivo in non clear cell



THANK YOU!

[daniel.heng@ahs.ca](mailto:daniel.heng@ahs.ca)

@DrDanielHeng

